This week’s episode will examine how graft versus host disease in the colon is driven by an inflammatory cytokine produced by specialized donor T cells, review a prospective, multicenter study to assess the frequency and clinical relevance of low level mutations in chronic myeloid leukemia, and learn about a potential new therapeutic that blocks the activity of the iron-regulatory hormone Erythroferrone to reduce iron overload in thalassemia.